GSK’s Bid For Human Genome Sciences: A Deal Decades In The Making
This article was originally published in The Pink Sheet Daily
Executive Summary
GlaxoSmithKline swoops in to acquire its research partner Human Genome Sciences – made vulnerable by the weak launch of Benlysta – for $13 per share in cash, or about $2.6 billion.